David A. Siegel Provention Bio, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $338,547 - $791,693	74,900 New	74,900 $791,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $73,014 - $107,457	-12,900 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.71 - $11.04 $5.96 Million - $9.8 Million	-887,500 Reduced 98.57%	12,900 $109,000
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $3.33 Million - $6.4 Million	328,800 Added 57.52%	900,400 $9.45 Million
Q4 2020 Feb 16, 2021	BUY	$11.79 - $18.94 $222,830 - $357,966	18,900 Added 3.42%	571,600 $9.68 Million
Q3 2020 Nov 16, 2020	BUY	$10.34 - $15.2 $4.94 Million - $7.26 Million	477,500 Added 634.97%	552,700 $7.09 Million
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $587,312 - $1.28 Million	75,200 New	75,200 $1.06 Million

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.